Skip to main content
. 2022 Jan 21;22:53. doi: 10.1186/s12884-021-04343-x

Table 3.

Individual Measures of Prenatal Care Utilization in Pregnant Women Who Consider but Do Not Have Abortions (Contemplators) Compared to Controls (Non-Contemplators)

Contemplators
n (%)
Non-Contemplators
n (%)
P-valuea Adjusted odds ratiob (95% CI)
Total, n = 277 n = 94 n = 183
Prenatal visit attendance
 High (80% or more) 60 (63.8%) 126 (68.9%) 0.40 1.1 (0.47 – 2.42)
 High medium (60%-80%) 16 (17.0%) 41 (22.4%) 0.29 0.7 (0.27 – 1.76)
 Medium (40%-60%) 9 (9.6%) 13 (7.1%) 0.47 1.0 (0.20 – 5.01)
 Low medium (20%-40%) 3 (3.2%) 2 (1.1%) 0.21 0.8 (0.05 – 14.86)
 Low (20% or lower) 6 (6.4%) 1 (0.5%)  < 0.01 7.5 (0.58 – 97.75)
First appointment by 12 weeks 20 (21.3%) 151 (82.5%)  < 0.01 0.3 (0.13 – 0.79)
Aneuploidy screening/genetic testing 59 (62.8%) 159 (84.2%)  < 0.01 0.7 (0.27 – 2.06)
Carrier screening 38 (40.4%) 96 (52.5%) 0.58 0.6 (0.30 – 1.36)
Sexually transmitted vaginal infection screening 91 (96.8%) 146 (79.8%)  < 0.01 1.3 (0.22 – 6.92)
Infectious serology screening 90 (4.3%) 175 (4.4%) 0.96 0.2 (0.02 -1.00)
Blood Panel 75 (79.8%) 179 (97.8%)  < 0.01 0.7 (0.13 – 3.83)
1-hour glucose tolerance test 73 (77.7%) 169 (92.3%)  < 0.01 0.4 (0.12 – 1.61)
Influenza immunization 57 (60.6%) 121 (66.1%) 0.37 0.8 (0.34 – 1.95)
Tdap immunization 76 (80.9%) 110 (60.1%)  < 0.01 7.8 (2.53 – 23.83)
Pap smear screening 87 (92.6%) 166 (90.7%) 0.61 2.1 (0.54 – 8.27)
Cervical length screening 70 (74.5%) 151 (82.5%) 0.11 0.8 (0.35 – 2.18)
Group B streptococcus screening 79 (84.0%) 164 (89.6%) 0.18 0.7 (0.20 – 2.65)
Anatomic ultrasound completed 62 (66.0%) 131 (71.6%) 0.62 0.9 (0.39 – 2.25)
Antepartum contraception counseling 73/88 (83.0%) 94/109 (86.2%) 0.52 0.9 (0.24 – 3.24)
Antepartum breastfeeding anticipatory guidance 75/88 (85.2%) 94/106 (88.7%) 0.48 0.6 (0.17 – 2.25)

aAll P-values calculated using chi-square test

bAdjusted for maternal characteristics of: race, age, insurance type, education, prior termination, tobacco use in pregnancy, substance use in pregnancy, depression in pregnancy, STI in pregnancy, and gestational age at presentation to prenatal care